iShares Biotechnology ETF $IBB Shares Sold by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC lessened its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 3.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 8,186 shares of the financial services provider’s stock after selling 266 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in iShares Biotechnology ETF were worth $1,047,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in IBB. Citigroup Inc. lifted its holdings in shares of iShares Biotechnology ETF by 88.5% in the first quarter. Citigroup Inc. now owns 3,208,144 shares of the financial services provider’s stock valued at $410,322,000 after buying an additional 1,505,976 shares during the period. Madrona Financial Services LLC lifted its holdings in shares of iShares Biotechnology ETF by 153.0% in the first quarter. Madrona Financial Services LLC now owns 81,150 shares of the financial services provider’s stock valued at $10,379,000 after buying an additional 49,075 shares during the period. GAMMA Investing LLC lifted its holdings in shares of iShares Biotechnology ETF by 12,698.7% in the first quarter. GAMMA Investing LLC now owns 48,251 shares of the financial services provider’s stock valued at $6,171,000 after buying an additional 47,874 shares during the period. GTS Securities LLC lifted its holdings in shares of iShares Biotechnology ETF by 3,266.0% in the fourth quarter. GTS Securities LLC now owns 46,720 shares of the financial services provider’s stock valued at $6,175,000 after buying an additional 45,332 shares during the period. Finally, Erste Asset Management GmbH lifted its holdings in shares of iShares Biotechnology ETF by 61.5% in the first quarter. Erste Asset Management GmbH now owns 63,000 shares of the financial services provider’s stock valued at $8,058,000 after buying an additional 24,000 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of iShares Biotechnology ETF stock opened at $143.80 on Friday. The business has a fifty day simple moving average of $135.45 and a 200-day simple moving average of $129.14. iShares Biotechnology ETF has a fifty-two week low of $107.43 and a fifty-two week high of $150.57.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.